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ABSTRACT 
In evaluating new oncology medicines, two common modelling approaches are state transition 
(e.g., Markov and semi-Markov) and partitioned survival (PS) models. PS models have become 
more prominent in oncology health technology assessment processes in recent years. Our 
experience in conducting and evaluating models for economic evaluation has highlighted many 
important and practical pitfalls. As there is little guidance available on best practices for those 
who wish to conduct them, we provide guidance in the form of "Key steps for busy analysts", who 
may have very little time and require highly favorable results.  
 
Our guidance highlights the continued need for rigorous conduct and transparent reporting of 
economic evaluations regardless of modeling approach taken, and the importance of modeling 
that better reflects reality which includes better approaches to considering plausibility, estimating 
relative treatment effects, dealing with post progression effects, and appropriate characterization 
of the uncertainty from modeling itself. 
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Three Learning Points 
· There is an increasing use of partitioned survival (PS modelling) for the economic 
evaluation of oncology drugs, without widely available practical guidance for conducting 
these types of models. Understanding what not to do is intended to raise awareness and 
improve analyses that are submitted to HTA bodies. 
· Structural assumptions made about extrapolation, relative treatment effects and what 
happens post-progression will often have a significant impact on estimates of cost-
effectiveness. Analysts need to be clear about these assumptions and provide a means 
to analyze alternative assumptions for HTA bodies and the decision-makers they support.  
 
· While there are both benefits and limitations to the different modelling approaches, the 
simplicity of PS modelling in particular may lend itself to oversimplifying structural 
assumptions. Given the widespread use of modelling in oncology HTA, we hope more 
analysts will employ good practices and that the demand for good practices will increase. 
 
TEXT  
Introduction 
The use of health technology assessment (HTA) as a policy tool to support healthcare decisions, 
particularly for new medicines, continues to grow in prominence. At the same time, there has 
been an increased reliance on economic evaluation based on modelling[1], as clinical evidence is 
developed primarily to support regulatory decisions of whether a technology is safe and 
efficacious rather than addressing payer concerns of whether it is truly a good use of 
resources.[2]  
 
Although standards for the conduct of health economic evaluation have not changed considerably 
in recent years[3], there has been increasing attention to modelling approaches, including tools 
for critical appraisal and best practices.[4] There has also been an evolution in the types of 
decisions and policies economic evaluation can support, including optimal care pathways, 
reimbursement decisions, and pricing agreements as well as recognition of the limitations of 
economic evaluation as a means to control expenditure growth in highly politicized contexts.[5]  
 
Internationally, as well as in Canada, medicines for oncology have grown in both political and 
financial importance.[6] Demand for early access to oncology interventions and regulatory 
approval based on non-comparative or early clinical data without information about long-term 
impact on costs and health, have made this area particularly challenging for payers and the HTA 
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bodies that support them. It has also increased the necessity of modelling and extrapolation, as 
well as invited guidelines, debate and commentary about appropriate methods.[7–11]  
 
In evaluating new oncology medicines, two common modelling approaches are state transition 
(e.g., Markov and semi-Markov) and partitioned survival (PS) models. The latter, also referred to 
as quality-adjusted survival analysis[12–14], is an area-under-the-curve modelling approach 
similar to Q-TWIST[15], in which average survival (and life-years) are calculated from overall 
survival curves.  
 
PS models were developed as a method of estimating average time in ‘alive’ health states in 
individuals with progressive disease[12]. They were originally devised as a way of avoiding 
challenges with the effect of patient attrition on health-related quality of life measurement in these 
post-progression states.[12] A typical three-state PS model requires an overall survival (OS) 
curve as well as another curve to partition between ‘alive’ states, which in oncology is typically a 
state of pre-progressed disease. Average time in one or more “progressed but alive” (i.e., post-
progression survival) states can then be calculated by subtracting the area between the curves 
with discounting if appropriate.  
 
The incentive to use PS models is likely driven from HTA demands to evaluate the consequences 
of decisions to use new medicines that go beyond the timeframes of clinical trials potentially 
coupled with lack of direct comparative information and available patient-level data. Requiring 
fewer assumptions and data than state transition models, they may in some sense align with 
guidance that emphasize model simplicity.[4]  Membership in partitioned states in PS models can 
be directly informed from extrapolated survival curves without the need for deriving individual 
transition probabilities between states. Like traditional state transition models, both costs and 
health state preference values (i.e., utilities) can then be assigned for the purpose of economic 
evaluation.  
 
Many funding recommendations about new medicines in Canada and abroad have been based 
on PS models. A review of the 30 most-recent NICE cancer drug appraisals (from May 2013 to 
Feb 2016) revealed PS modelling informed 73% (22/30) of them.[11,16] Model structure issues, 
particularly those frequently associated with PS models such as extrapolation and assumptions of 
benefit post-progression, have also been shown to correlate with negative recommendations from 
the pan-Canadian oncology review (pCODR).[17] In the past several years, PS models have 
been used in the majority of new oncology drug submissions to pCODR. 
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Despite the widespread use of modelling for oncology in HTA, there is little guidance available on 
current best practices, particularly for those who wish to use PS models. This note seeks to fill 
this gap, and shares thoughts on how to conduct and report economic evaluations with an 
emphasis on the emerging practice of PS modelling, based on our collective experience in 
conducting, evaluating and interpreting them.  
 
With tongue firmly in cheek, we provide our recommendations in the form of “Key steps for busy 
analysts”, who may have incentives to achieve favorable results and have very little time (and 
data) to produce them.  
 
Step 1 – Avoid current standards for conduct and reporting of economic evaluations 
 
Current international best practices for the conduct and reporting of economic evaluation 
emphasize the need to conceptualize models, and explain and justify approaches.[4,18,19] In 
many cases, the most appropriate approach is not clear—however, in principle, cancer can 
always be conceptualized in at least three health states--- progression free, survival post-
progression, and dead (Figure 1). Although uncertainty about what occurs post-progression may 
be more readily explored with state transition modelling approaches, PS models are very 
convenient because they align with trial endpoints as presented in most publications, and can be 
derived from summary information and survival curves for treatments that are usually presented. 
Their use of observed survival curve data may also make them seemingly easier to interpret for 
decision-makers. If one feels pressure to explain why a PS modelling approach was necessary, 
some popular explanations are that the choice to use a PS model was based on 1) its popularity, 
2) precedence in terms of use in previous analyses, or 3) convenience given available data.[20] 
Be careful when using these justifications! Good practice suggests decision problems rather than 
data availability should drive the modelling approach taken.[4]  
 
Decision-makers may want a model that goes beyond these simple health states and additionally 
considers discontinuation rates, adverse events, downstream treatment, treatment switching, 
drug wastage, appropriate comparators and other patient-relevant considerations. Accounting for 
these potentially important factors will require more effort and more data regardless of the 
modelling approach taken.  PS modelling effectively precludes explicit consideration of the 
influence on progression or survival of successive lines of treatment relevant to your healthcare 
setting, especially if the trial ended early or these treatments were not (yet) used by patients in 
the trial.[21] To avoid extra work, one could 1) tell local decision-makers that the care pathways 
used in the trial are not generalizable but an unrecognized standard of care OR 2) that these trial-
based care pathways are generalizable and will perform similarly to whatever has been 
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implemented in their own jurisdictions. The additional steps required to conceptualize and 
incorporate all details relevant to the decision problem can be tiresome for the busy analyst with 
little time. 
 
Avoiding or misreporting other important details of the evaluation can also curtail scrutiny. A good 
first step, for example, is to use the terms PS model, state transition model, semi-Markov[22], or 
Markov[23] model interchangeably to avoid criticism. One may also want to avoid reporting the 
value of resources or health (e.g., quality-adjusted life-years or life-years gained) that accrues in 
the pre- and post-progression states separately. This is particularly important when extrapolation 
methods are employed that result in substantial benefits accrued after progression of cancer, 
when therapy is halted, and without an underlying rationale to support it. (See Step 4) 
 
Of course, there are also many methodological choices that will help to achieve favorable results 
that have little to do with modelling per se.[24] One will find the standard approaches to lowering 
incremental cost-effectiveness ratios (ICERs) still work here: 1) Carefully select health state 
preference values (i.e., utilities – use high ones for progression free and avoid a wide range of 
estimates); 2) Use inappropriate or less effective comparators when possible; 3) Calculate 
average cost-effectiveness ratios rather than incremental ones (try also not to report the 
numerator or denominator of these ratios); 4) Use inappropriate or difficult-to-scrutinize costing 
methods and 5) avoid disaggregating resource use measures / costs wherever possible.  
 
Step 2 – Maximize survival benefits through extrapolation! 
A three-state model (progression free, progressed disease, dead) first requires time-to-event data 
for progression and death. For PS models, these can be derived from progression-free survival 
(PFS) and OS endpoints using aggregate (i.e., survival curves) or individual patient data for either 
treatment or comparator (or both, see Figure 1). Extrapolation from trial data generally requires a 
semi- or, more commonly, fully-parametric method for generating survival analysis curves.[10] 
Survival analysis curves may be generated from trial data of a new intervention itself, or using 
evidence from another study, disease registry, or meta-analysis.[8,10] State transition models 
require additional data to reliably determine probabilities between states, including transition to 
death post-progression. 
 
Existing guidance intended to make the selection of a statistical extrapolation method transparent 
and consistent between analyses requires analysts to present an “assessment of the fit of all 
available parametric models, details on the statistical fit of alternative models, tests of 
proportional hazards, consideration of the expected pattern in the hazard over time, and a 
comparison to external or registry data.”[8] -- a lot of work! The first and obvious approach to 
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producing better results is to handpick parametric approaches and not systematically apply 
recommended selection criteria, based on a combination of visual inspection, statistical tests, and 
appropriate justification with respect to internal and external validity. A flowchart that summarizes 
a useful way to apply these criteria has been published that the busy analyst may also need to 
ignore.[8] If the steps in the flowchart need to be addressed, you may want to consider selecting 
curves that are statistically appropriate, but ignore clinical plausibility. This is a common 
approach. For example, of 32 NICE technology assessments that used a parametric model-
based extrapolation technique, only one used external data as a means of testing the plausibility 
of extrapolation.[25] Luckily establishing external validity involves some judgment and 
conventional approaches are not yet established.[10] 
 
A “quick and dirty” approach to extrapolation that may work is to show a few carefully selected 
curves and use the ones that appear to fit best to the existing trial data through “visual inspection” 
or a subset of tests alone. The shorter the observed data relative to the time horizon over which 
you wish to extrapolate, the more opportunity you have to fit curves that align well with observed 
data but still display a range of long-term projections. Once plausible alternative models are 
discarded outright, it should then be easier to justify not including these in the economic model or 
conducting the sensitivity of results to these choices.  
 
The advantage of PS models based on single parametric forms is that it is more difficult to test 
the sensitivity of the results to assumptions about extrapolation since transitions are not explicitly 
modelled.[11] This may also create the appearance of less uncertainty! Although much more 
useful to decision-makers, try not to create a model that allows users to test the sensitivity of 
results to varying parametric forms. You may also want to stick to single parametric forms that 
assume observed events from the trial predict future ones in a straightforward fashion rather than 
more flexible approaches (e.g., piecewise using multiple forms, spline-based, or mixture cure 
models) that may be more clinically plausible. Be warned that model users unable to change 
extrapolation parameters may use alternate (and less accurate) approaches to sensitivity 
analyses such as reducing the time horizon as a means to modifying extrapolated survival 
benefits that are seen as unrealistic or are associated with uncertainty. Be aware, negative 
funding recommendations have been associated with concerns about uncertainty due to 
inappropriate extrapolation over large time horizons.[17] 
Step 3 – Be creative when estimating relative treatment effects 
Economic evaluation requires knowing the effect of treatment on progression and survival. This 
can be estimated from a trial with a relevant comparator directly. In many cases, locally relevant 
comparators have not been used in clinical trials, or the analyst will only have data from a single-
arm study without a comparator. Don’t panic! Comparative treatment effects can be estimated 
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without direct evidence using a variety of exploratory statistical approaches. However, when 
models are based on survival analysis curves, a fun and easy approach is to overlay the PFS and 
OS curves derived from a study of your new therapy of interest directly on top of curves from 
other studies to create an unadjusted but compelling indirect comparison. Survival is a hard 
outcome, and (fingers crossed), those examining your analysis will focus on the intervention as 
the sole explanation for outcomes rather than adjusting for the influence of differences in study 
populations (e.g., gender, age, performance status, etc.), care pathways, trial procedures, or 
other analytic choices. 
 
If unadjusted comparisons are not an option, you may need to consider newer approaches to 
indirect treatment comparison, such as matching-adjusted indirect comparison or propensity-
score match-adjusted comparisons as a means to creating comparisons.[26] Indirect treatment 
comparisons are easiest to incorporate into a model when studies used to generate relative 
treatment effects are handpicked (rather than based on a systematic review)! Making the 
statistical code or original data sets unavailable to reviewers can prevent immediate scrutiny. Try 
again to steer away from current conduct and reporting guidelines for indirect treatment 
comparisons.[27,28] Their singular focus on justifying methods, accounting for important 
confounders and not breaking randomization will increase your workload!  
 
Another awkward situation is that OS results from clinical trials may not reach clinically or 
statistically meaningful endpoints. As most people are willing to believe this is a result of the trial 
design rather than the drug, it also means the analyst must adjust for the impact of trial design 
factors such as crossover using individual patient data and justify assumptions required for these 
methods.[29] A quicker (and dirtier) solution can be found in estimating OS from a different 
source of information entirely. While this may not be easy to justify (just say “individual patient 
data weren’t available”), there could most certainly be plenty of other trials or registries to choose 
from.  
 
Another fast solution is to simply apply a hazard ratio derived from a PFS curve and apply this to 
the OS curve. This assumes any time spent delaying progression will translate directly into 
survival benefits! Any application of constant hazard ratios also relies on the typically unrealistic 
assumption of constant proportional hazards over time, and independence of outcomes. Luckily, 
analysts infrequently test and report on these assumptions[30], and ignoring them can translate 
into significantly more QALYs than could be calculated directly from trial data. 
 
Differences in survival can be further exaggerated in PS models when OS and PFS curves for the 
treatment and comparator groups are extrapolated independently (e.g., using different parametric 
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forms that imply different assumptions about the hazard function). State transition models using 
fitted approaches or modelling state transitions from individual patient data (i.e., multi-state 
modelling)[31] is more time consuming but can achieve the same result.[31,32] Be aware 
modelling survival independently may actually be fully justified in some cases, such as when the 
effect on PFS does not directly translate into a survival benefit or when the treatments being 
compared have different mechanisms of action, but the appropriateness of such assumptions are 
hard to assess either way. A quicker approach is to fit a parametric curve to one trial arm then 
apply a hazard ratio (without checking the proportional hazard assumption) from the trial to 
predict comparative effectiveness.[33] Tip: you may find more favorable ICERs from applying a 
hazard ratio to a comparator curve, rather than the other way around. Play around with this! 
Ultimately, you will find approaches that lower your ICER. The key is to downplay the sensitivity 
of the results to these many different structural assumptions.  
 
Step 4 – Make simplifying assumptions about what happens post-progression 
Even if you do all the hard work of estimating relative treatment effects using an approach that 
passes scrutiny, and this increases your ICER past your comfort zone, no worries, there is still a 
final opportunity to get the ICER where you want! A simplifying assumption often made in either a 
PS or state-transition model is that the treatment effect persists for the duration of the time 
horizon. Do not consider any changes in relative benefits over time, particularly any waning of 
treatment effect; you will have to ignore guidance[34] about this assumption as well. This can be 
characterized by hazard ratios that are constant (i.e., continued benefits) for the entire time 
horizon of a model, or with independently fit parametric survival functions that consistently 
assume lower hazards for the treatment arm than the comparator. For PS models, this works very 
well because they assume the risk of death in each treatment group is a function of time, whereas 
in reality, risk of death is usually a function of both time and health state. It also works particularly 
well when OS curves are already extrapolated optimistically.  
 
While it is possible that a failure to account for the impact time in a progressed state has on 
mortality risk will not significantly impact results, be mindful this is a gross simplification and could 
be questioned. Moreover, a new therapy can directly increase the risk of dying after progression 
by making downstream treatments less effective. The new therapy can also appear to indirectly 
increase the risk of dying after progression through a selection bias, by reducing progression in 
healthier people at a lower risk of death.[35] It is also possible for new therapies to reduce the risk 
of dying post-progression. The good news for the analyst requiring less work is that there are 
often not enough data to check assumptions about the impact of progression – so the analyst 
may assume the same risk continues unabated and that hazards are not dependent on the 
progression event nor the time spent in a progressed state.   
 10 
 
It is worth mentioning that the lack of individual patient-level data for creating reliable transition 
probabilities is your strongest ally. Luckily for analysts, manufacturers are not compelled to share 
these data and HTA bodies may not demand them. Without these data, models are limited to 
estimates based on extrapolations of the aggregate clinical trial endpoint data. The availability of 
IPD provides more flexibility, allowing direct estimation of treatment effects and adjustment for 
treatment switching in PS models, and for estimation of additional transitions such as that from 
progression to death, ideally by estimating all transition probabilities simultaneously using a multi-
state approach. However, you may find that these approaches can change ICERs  
dramatically.[36] You may also need to deal with biases that arise from incomplete OS data.[35] 
Unfortunately, increased data sharing and availability may become a reality in the future[37], 
which could make it more difficult to make excuses and keep ICERs in the sweet spot! 
Remember, in oncology modelling, the less we know the better!  
 
When PFS and OS curves are extrapolated independently within PS models, you may also run 
into a tricky situation where there are a higher percentage of people in the progression-free state 
than are actually alive. A bit hard to explain! Rather than changing your extrapolation parameters, 
you may simply want to downward adjust PFS benefits at the tail to account for this. If scrutinized, 
additional, more nuanced, methods have been developed to potentially deal with this issue[38,39] 
They are less conventional, but may actually more accurately reflect the natural history of 
disease. A ‘piecewise’ approach which changes hazards at certain time points, may be more 
practical,[39] but again will require a bit more work. 
 
An illustrative example of some of the many approaches to handing uncertainty in steps 2-4 is 
shown below (Figure 2). The figure shows that once the trial ends, the analyst can produce a 
wide range of differences in extra effects (ΔE) depending on whether considering only the 
observed data, assuming the relative benefit (OS HR) continues unabated indefinitely, or 
exploring piece-wise changing hazards that represents diminishing benefits over time. In this 
simple hypothetical example, these scenarios produce 5-fold differences in estimates of extra 
effect including a nearly two-fold difference between scenarios of relative benefits continuing or 
diminishing over time.  
 
Step 5- Assume no structural uncertainty 
The final step for the analyst interested in quick-and-favorable results is to assume the model 
provided represents an uncontestable and definitive analysis for the decision maker. The good 
news is that neither PS or state-transition models have been shown to always produce more 
favorable results and that there is still little empirical work illustrating differences in these 
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approaches.[36,40–42] Also encouraging is that unlike modelling in other fields, such as weather 
forecasting[43] and climate change[44], one modelling approach in healthcare, even for 
multimillion-dollar decisions, is often seen as acceptable! History trumps reason. Although 
sensitivity analyses can be conducted using plausible ranges of the larger number of 
assumptions that go into modelling, they will require a lot of time and effort. [45] Some 
hardworking analysts have even conducted both state transition and PS modelling approaches as 
a means to check the impact of structural assumptions; however, this is still the exception to the 
rule! [36,40–42,46] 
 
CONCLUDING REMARKS 
We hope this tongue-in-cheek advice will be useful for the hurried analyst. Luckily, there are no 
one-size-fits-all approaches in the area of oncology modelling, and a lot of room to manoeuver. 
As future empirical research emerges and methods become more established, we hope new 
avenues for creativity will emerge.  
 
(MORE SERIOUS) CONCLUDING REMARKS  
Despite some concerns raised about the use of oncology models in HTA, there seems to be no 
concrete evidence that any one approach systematically produces better or worse results than 
other approaches. It is possible that the more straightforward approach in PS modelling lends 
itself more to the various shortcuts and potential pitfalls highlighted here. We hope this guide 
reinforces the need for rigor in the conduct of oncology modelling, and the sensitivity of the 
results to the numerous choices made to conduct them. Given their prominence in HTA to 
support funding anticancer therapies, coupled with the large number of medicines being 
developed, and their potential additional costs, we hope more analysts will employ good practices 
and that the demand for good practices will increase. Understanding the impact of choices in 
analytic judgments, at the very least, requires transparent and consistent reporting of methods 
and results. 
 
In addition to the need for rigorous conduct and transparent reporting of economic evaluations, 
we hope our ‘Key steps for busy analysts’ also highlight the importance of modelling that better 
reflects reality; this includes better approaches to considering plausibility, estimating relative 
treatment effects, dealing with post progression effects, and appropriate characterization of the 
uncertainty from modelling itself. They may also highlight the need for more time and better 
reporting for those who are fortunate enough to conduct and review these analyses. We would 
argue there is a need for elevated rigor and transparency of reporting regardless of what type of 
model is chosen. Perhaps the final frontier will be less focus on the final result, and more on how 
the result was achieved, and whether it really makes sense. 
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Figure 1. Three state conceptual model for cancer.  
OS = Overall survival. Cancer can usually be conceptualized as a three state model with patients 
either alive or dead. Patients in an alive state have either yet to progress (i.e., have achieved an 
endpoint of progression-free survival) or have clinically significant disease (i.e., have achieved an 
endpoint of progressed disease, calculated by subtracting overall survival from progression free 
survival). Patients can die in either state, which is the inverse of their probability of being alive (1 
– OS). . 
 
 
 
Progressionfree
Probability =
Progression free survival
(PFS)
Alive
Progressed
disease (PD)
Probability = 1-OS-PFS
Dead
Probability = 1-OS
 17 
 
 
Figure 2. Illustration of effect on incremental cost-effectiveness of greatly differing 
assumptions related to benefits from  extrapolation of overall survival in a PS model 
When modelling based on trial data with a follow-up period that is short (6-12 months) relative to 
the time period relevant for decision-making (10-12 years), the relative effect of treatment (Δ E) is 
greatly affected by structural assumptions related to how benefits continue beyond the period of 
the trial (extrapolation) and relative to standard therapy post-progression. Basing calculations on 
benefits observed in the trial could provide the smallest estimates, whereas assuming benefits 
seen in the trial continue for as long patients are alive will provide large ones. Structural 
assumptions made about extrapolation, what happens in each treatment arm post-progression 
and how relative treatment effects are ascertained (not shown here) often have a larger impact on 
estimates of effectiveness than any other factors. Being very clear about how these assumptions 
were made and making them amenable to change by decision-makers is important and may be 
ignored by the busy analyst. 
 
 
